Oxytocin and CBSST for People With Schizophrenia
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT01752712 |
Recruitment Status :
Completed
First Posted : December 19, 2012
Results First Posted : October 31, 2017
Last Update Posted : September 25, 2019
|
- Study Details
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Schizophrenia Schizoaffective Disorder | Drug: CBSST + Oxytocin Drug: CBSST + Placebo | Not Applicable |

Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 83 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | Triple (Participant, Care Provider, Investigator) |
Primary Purpose: | Treatment |
Official Title: | Combined Oxytocin and CBSST for Social Function in People With Schizophrenia |
Study Start Date : | January 2014 |
Actual Primary Completion Date : | August 2016 |
Actual Study Completion Date : | August 2016 |

Arm | Intervention/treatment |
---|---|
Experimental: CBSST + oxytocin
Cognitive Behavioral Social Skills Training with adjunct oxytocin nasal spray treatment. Participants will receive 80 IU/day of oxytocin administered intranasally in two doses (40 IU morning and evening).
|
Drug: CBSST + Oxytocin
The oxytocin dose of 80 IU/day, will be administered in two divided doses: 40 IU in the morning and 40 IU in the evening. Oxytocin will be administered intranasally (10 puffs of the spray, 5 in each nostril at each administration). CBSST groups will occur for an hour twice/week. Nasal spray will be administered an hour prior to the CBSST group. |
Placebo Comparator: CBSST + placebo
Cognitive Behavioral Social Skills Training with placebo nasal spray. The placebo nasal spray bottles will be matched in appearance to the oxytocin nasal spray bottles and similarly administered intranasally in two doses (morning and evening).
|
Drug: CBSST + Placebo
Matching placebo spray will be administered intranasally (10 puffs of the spray, 5 in each nostril at each administration). CBSST groups will occur for an hour twice/week. Nasal spray will be administered an hour prior to the CBSST group.
Other Name: sugar pill |
- Birchwood Social Function Scale (BSFS) Total Score [ Time Frame: Treatment weeks 0, 12, and 24, plus follow-up week 36 ]Determine if CBSST + oxytocin compared to CBSST + placebo is associated with improved social function. There are 7 individual sections, with each section asking about different aspects of social functioning. Scores for Section 1: "Social Engagement Withdrawal" range from 0-15; Section 2: "Interpersonal Communication/Relationships" ranges from 0-30; Section 3: "Prosocial Activities" range is 0-66; Section 4: "Recreation" ranges from 0-48; Section 5: "Independence (Performance)" ranges from 0-39; Section 6: "Independence (Competence)" ranges from 0-39; and Section 7: "Occupation/Employment" ranges from 0-6 if the participant is unemployed or 7-10 if the participant is employed. The minimum value possible is 0 for participants who are unemployed and 7 for those with employment. The total BSFS score is calculated by adding the total scores from each of the 7 sections, with a maximum total score of 247. A lower total score indicates a lower social function rating.
- Defeatist Performance Attitudes Scale (DPAS) Total Score [ Time Frame: Treatment weeks 0, 12, and 24, plus follow-up week 36 ]Determine if CBSST + oxytocin compared to CBSST + placebo is associated with defeatist performance beliefs. The total DPAS score is calculated by adding the scores for scales #1-#18. Each scale ranges from "1=Agree Totally" to "7=Disagree Totally". Total scores range from a minimum score of 18 to a maximum score of 126. Reverse scoring was applied to make higher scores indicate a stronger defeatist attitude.
- Asocial Belief Scale (ABS) Total Score [ Time Frame: Treatment weeks 0, 12, and 24, plus follow-up week 36 ]Determine if CBSST + oxytocin compared to CBSST + placebo is associated with asocial beliefs. The total ABS score is calculated by adding the scores for items #1-#15. Each scale is provided a True/False response, with True responses equaling 1 point and False responses equaling 0 points. In calculating the ABS total score, four of the 15 items of the ABS were reverse scored. A lower total score indicates more severe asocial beliefs.
- Schedule for Assessment of Negative Symptoms (SANS) Total Score [ Time Frame: Every 4 weeks during the treatment phase, plus follow-up week 36 ]SANS total score range = 0-85. Higher scores indicate more severe negative symptoms.
- Brief Psychiatric Rating Scale (BPRS) Total Score [ Time Frame: Every 4 weeks during the treatment phase, plus follow-up week 36 ]The total BPRS score is calculated by adding the scores for scales #1-#18. Each scale ranges from "1=Not Present" to "7=Very Severe". Total scores range from a minimum score of 18 to a maximum score of 126. A higher total score indicates a more severe psychiatric symptom rating.
- Brief Psychiatric Rating Scale (BPRS) Psychosis Score [ Time Frame: Every 4 weeks during the treatment phase, plus follow-up week 36 ]The psychosis score is calculated by adding the scores for scales #4 Conceptual Disorganization, #11 Suspiciousness, #12 Hallucinatory Behavior, and #15 Unusual Thought Content. Each scale ranges from "1=Not Present" to "7=Very Severe". The minimum psychosis score is 4 and the maximum psychosis score is 28. A higher score indicates a more severe psychosis rating.

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years to 55 Years (Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- DSM-IV-TR diagnosis of schizophrenia or schizoaffective disorder
- Scale for the Assessment of Negative Symptoms asociality item score ≥ 2
- Considered clinically stable by the treating psychiatrist
- Stable treatment with the same antipsychotic for at least 60 days and the same dose for at least the 30 days prior to study entry.
- Male or female of any race.
Exclusion Criteria:
- Organic brain disorder, including cerebrovascular accident; epilepsy; traumatic brain injury, loss of consciousness (LOC) for more than 30 minutes
- Mental retardation
- Medical conditions, whose pathology or treatment could alter the presentation or treatment of schizophrenia or significantly increase the risk associated with the proposed treatment protocol
- Participant is pregnant or is lactating
- History of chronic allergic rhinitis
- DSM-IV-TR diagnosis of alcohol or substance dependence (except nicotine) within the last 6 months, or participant has met dependence criteria for 5 years or more.
- DSM-IV-TR diagnosis of alcohol or substance abuse (except nicotine) within the last month
- Participant has a past history of polydypsic hyponatremia (defined by sodium levels below 130 mmol/L) or has a current sodium level below 135 mmol/L
- Participant with EKG evidence of any of the following cardiac arrhythmias: QTc prolongation (Males: 450 msec or greater; females: 470 msec or greater); atrial fibrillation; ventricular or supraventricular tachycardia; and 2nd or 3rd degree A-V Block

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01752712
United States, California | |
University of California, San Diego | |
San Diego, California, United States, 92093 | |
United States, Maryland | |
Maryland Psychiatric Research Center | |
Baltimore, Maryland, United States, 21228 |
Principal Investigator: | Robert Buchanan, MD | University of Maryland, College Park |
Responsible Party: | Robert Buchanan, Chief, Maryland Psychiatric Research Center, Outpatient Research Program, University of Maryland, Baltimore |
ClinicalTrials.gov Identifier: | NCT01752712 |
Other Study ID Numbers: |
HP-00054628 |
First Posted: | December 19, 2012 Key Record Dates |
Results First Posted: | October 31, 2017 |
Last Update Posted: | September 25, 2019 |
Last Verified: | November 2017 |
Oxytocin Social function CBSST |
Schizophrenia Psychotic Disorders Schizophrenia Spectrum and Other Psychotic Disorders Mental Disorders |
Oxytocin Oxytocics Reproductive Control Agents Physiological Effects of Drugs |